honokiol has been researched along with Pancreatic Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ahmad, A; Arora, S; Averett, C; Bhardwaj, A; Carter, JE; Khan, MA; Khushman, M; Singh, AP; Singh, S; Srivastava, SK | 1 |
Arora, S; Bhardwaj, A; McClellan, S; Singh, AP; Singh, S; Srivastava, SK; Wang, B | 1 |
2 other study(ies) available for honokiol and Pancreatic Neoplasms
Article | Year |
---|---|
Honokiol suppresses pancreatic tumor growth, metastasis and desmoplasia by interfering with tumor-stromal cross-talk.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biphenyl Compounds; Cell Communication; Cell Line, Tumor; Down-Regulation; Female; Gene Expression; Hedgehog Proteins; Humans; Lignans; Liver Neoplasms, Experimental; Lung Neoplasms; Mice; Pancreatic Neoplasms; Receptors, CXCR4; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells.
Topics: Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Biphenyl Compounds; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; G1 Phase; Gemcitabine; Humans; Lignans; NF-kappa B; Pancreatic Neoplasms; Protein Transport | 2011 |